Россииское кардиологическое общество Российское научное медицинское общество терапевтов Антигипертензивная лига
 Скачать 3.62 Mb.
|
|
Ray CS, Sue DY, Bray G, et al. Effects of obesity on respiratory function. Am Rev Respir Dis 1983;128:501-6. 330. Biring MS, Lewis MI, Liu JT, et al. Pulmonary physiologic changes of morbid obesity. AmJMedSci 1999;318:293-7. 331. Weiner P, Waizman J, Weiner M, et al. Influence of excessive weight after gastroplasty for morbid obesity on respiratory muscle performance. Thorax 1998;53:39-42. 332. Chlif M, Keochkerian D, Mourlhon C, et al. Noninvasive assessment of the tension-time index of inspiratory muscles at rest in obese male subjects. Int J Obes (Lond) 2005;29:1478-83. 333. Бойков В. А. и др. Состояние функции внешнего дыхания у пациентов с ожирением // Бюллетень сибирской медицины. 2013. Vol. 12. № 1. С. 86–92. 334. Sin DD, Jones RL, Man SF. Obesity is a risk factor for dyspnea but not for airflow obstruction. Arch Intern Med 2002;162:1477-81. 335. Sharp JT, Henry JP, Sweany SK, et al. The total work of breathing in normal and obese men. J Appl Physiol 1964;43:728-39. 336. LeBlanc P, Bowie DM, Summers E et al. Breathlessness and exercise in patients with cardiopulmonary disease. AmRevRespirDis 1986;133:21-5. 337. Guerra S, Sherrill DL, Bobadilla A et al. The relation of body mass index to asthma, chronic bronchitis, and emphysema. Chest 2002;122:1256-63. 338. Pitta F, Troosters T, Spruit MA et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:972-7. 339. Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-12. 153 340. Schols AMW, Slangen J, Volovics L et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1791-7. 341. Vestbo J, Prescott E, Almdal T et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen city heart study. Am J Respir Crit Care Med 2006;173:79-83. 342. Gilliland FD, Berhane K, Islam T et al. Obesity and the risk of newly diagnosed asthma in school-age children. AmJEpidemiol 2003;158:406-15. 343. Guerra S, Wright AL, Morgan WJ et al. Persistence of asthma symptoms during adolescence: role of obesity and age at the onset of puberty. Am J Respir Crit Care Med 2004;170:78-85. 344. Lavoie KL, Bacon SL, Labrecque M et al. Higher BMI is associated with worse asthma control and quality of life but not asthma severity. Respir Med 2005. 345. Camargo CA Jr., Weiss ST, Zhang S et al. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med 1999;159:2582-8. 346. Kim S, Camargo CA Jr. Sex-race differences in the relationship between obesity and asthma: the behavioral risk factor surveillance system, 2000. Ann Epidemiol 2003;13:666-73 347. Tantisira KG, Weiss ST. Complex interactions in complex traits: obesity and asthma. Thorax 2001;56(Suppl 2):ii64-73. 348. Simard B, Turcotte H, Marceau P, et al. Asthma and sleep apnea in patients with morbid obesity: outcome after bariatric surgery. Obes Surg 2004;14:1381-8. 349. Aaron SD, Fergusson D, Dent R, et al. Effect of weight reduction on respiratory function and airway reactivity in obese women. Chest 2004;125:2046- 52. 350. Stenius-Aarniala B, Poussa T, Kvarnstrom J, et al. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ 2000;320:827-32. 351. Farag YM, Gaballa MR. Diabesity: anoverviewofarisingepidemic. Nephrol. Dial. Transplant2011.26, 28–35. 352. Influence of Obesity on the appearance of Proteinuria and Renal Insufficiency after Unilateral NephrectomyM Praga, E Hernández, JC Herrero, E Morales, Y Revilla, R Díaz-González, JL Rodicio.Kidney Int 2000; 58: 2111- 2118. 353. Wu et al. Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples Endocrinology. 2006;147:44-50. 354. Adelman R. D. Obesity and renal disease //Current opinion in nephrology and hypertension. – 2002. Vol. 11. № 3. P. 331–335. 355. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y: The effects of weight loss on renal function in patients with severe obesity. Am Soc Nephrol;14:1480-1486. 356. Chen HM et al. Obesity-related glomerulopathy in China: a case series of 90 patients. Am. J. Kidney Dis. 2008 52, 58–65. 357. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity- related glomerulopathy: an emerging epidemic. Kidney Int. 2001. 59, 1498–1509 154 358. Praga M. et al. Clinical features and long-term outcome of obesity- associated focal segmental glomerulosclerosis. Nephrol. Dial. Transplant. 2001.16, 1790–1798. 359. Kambham N., Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity- related glomerulopathy: an emerging epidemic. KidneyInt. 2001. 59, 1498–1509 360. Sethi S, Zand L, Nasr SH, Glassock RJ, Fervenza FC. Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations. Clin. Kidney J. 2014 7, 531–537. 361. Bosma RJ, van der Heide JJ, Oosterop EJ, de Jong PE, Navis G. Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. KidneyInt. 2004 65, 259–265. 362. Serra A et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int. 2008 73, 947–955. 363. Tsuboi N et al. Clinical features and long-term renal outcomes of Japanese patients with obesity-related glomerulopathy. Clin. Exp. Nephrol. 2013 17, 379– 385. 364. Chen HM et al. Evaluation of metabolic risk marker in obesity-related glomerulopathy. J. Ren. Nutr. 2011 21, 309–315. 365. Praga M. et al. Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition. Am. J. Kidney Dis. 1991 17, 330–338. 366. Gunter W, Sheldon C, Han DC et al. Leptin and renal disease. Am. J. Kidney Dis. 2002; 39: 1-11. 367. Baud L, Fouqueray B, Amrani PC. Tumor necrosis factor alpha and mesangial cells. Kidney Int. 1992; 41: 600-603. 368. Kohan DE. Endothelins in the normal and diseased kidney. Am. J. Kidney Dis. 1996; 1: 2-26. 369. White SL et al. Is low birth weight an antecedent of CKD in later life? A systematic review of observational studies. Am. J. Kidney Dis. 2009 54, 248–261. 370. de Jong F, Monuteaux MC, van Elburg RM, Gillman MW, Belfort MB. Systematic review and meta-analysis of preterm birth and later systolic blood pressure. Hypertension 2012. 59, 226–234. 371. Mu M et al. Birth weight and subsequent blood pressure: a meta-analysis. Arch. Cardiovasc. Dis. 2012.105, 99–113. 372. Vikse BE, Irgens LM, Leivestad T, Hallan S, Iversen BM. Low birth weight increases risk for end-stage renal disease. J. Am. Soc. Nephrol. 2008. 19, 151–157. 373. Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT: Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 2010 5: 1003–1009. 374. Naor N, Fellahi EJ. Potential Contribution of Adipose Tissue to Elevated Serum Cyctatin C in Human Obesity. Obesity 2009; 17. 2121-2126. 375. Morales E, Valero MA, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am. J. Kidney Dis 2003.. 41, 319–327. 376. Straznicky NE et al. Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. J. Hypertens. 2011 29, 553–564. 377. Navaneethan SD et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 2009 4, 1565– 1574. 155 378. Afshinnia F, Wilt TJ, Duval S, Esmaeili A, Ibrahim HN. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol. Dial. Transplant. 2010 25, 1173–1183. 379. Bolignano D, Zoccali C. Effects of weight loss on renal function in obese CKD patients: a systematic review. Nephrol. Dial. Transplant. 2013 28 (Suppl. 4), iv82–iv98. 380. MacLaughlin HL et al. Weight loss, adipokines, and quality of life after sleeve gastrectomy in obese patients with stages 3–4 CKD: a randomized controlled pilot study. Am. J. Kidney Dis. 2014 64, 660–663. 381. Chagnac A et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol. Dial. Transplant 2008. 23, 3946–3952. 382. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165:947–953. 383. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110:921–927. 384. Schmieder RE, Mann JF, Schumacher H, Gao P, Mancia G, Weber MA et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. JAmSocNephrol 2011; 22:1353–1364. 385. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk // Lancet. 2007; 369:1208–1219. 386. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the rennin angiotensin system on proteinuria in renal disease. AnnInternMed 2008; 148:30–48. 387. Bakris GL, Serafidis PA, Weir MR, Dalhof B, Pitt B, Jamerson K et al. Accomplish Trial Investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (Accomplish): a prespecified secondary analysis of randomised controlled trial. Lancet 2010; 375:1173–1181. 388. Mallamaci F et al. Ace inhibition is renoprotective among obese patients with proteinuria. J. Am. Soc. Nephrol. 2011 22, 1122–1128. 389. Garg R, Adler GK. Aldosterone and the mineralocorticoid receptor: risk factors for cardiometabolic disorders. Curr. Hypertens. Rep. 2015. 17, 52-65. 390. Bomback AS, Muskala P, Bald E, Chwatko G, Nowicki M. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage. Clin. Nephrol. 2009 72, 449–456. 391. Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell’Italia LJ, Cofield SS et al. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens 2012; 26:502–506. 392. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369:1208–1219. 393. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the rennin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148:30–48. 394. Коган М. И., Белоусов И. И., Шангичев А. В. Синдром хронической тазовой боли // ХП III: текущая точка зрения Ростовского медицинского 156 университета: Материалы IV Всероссийского конгресса «Мужское здоровье». М., 2008: 101–104. 395. Корнеев И. А., Глазнева С. Ю. Уровень тестостерона и расстройства мочеиспускания у больных с доброкачественной гиперплазией предстательной железы // Материалы IV Всероссийского Конгресса «Мужское здоровье». М., 2008: 49–50. 396. Курникова А. А., Шукшина Л. М. Взаимосвязь метаболических параметров и факторов воспаления при возрастном гипогонадизме // Материалы VI Российского конгресса «Мужское здоровье». М., 2010: 305– 306. 397. Лоран О. Б., Пушкарь Д. Ю., Сегал А. С. Наше понимание хронического простатита. Фарматека. 2002; 10: 69–75. 398. Калинченко С. Ю., Тюзиков И. А. Практическая андрология. М.: Практическая медицина, 2009. 400 с. 399. Goncharov NP, Katsya GV, Chagina NA et al. Three definitions of metabolic syndrome applied to a sample of young obese men and their relation with plasma testosterone. Aging Male 2008; 11:118–122. 400. Moebus S, Hanisch JU, Aidelsburger P, Bramlage P, Wasem J, Jockel KH. Impact of 4 different defi nitions used for the assessment of the prevalence of the metabolic syndrome in primary healthcare: the German Metabolic and Cardiovascular Risk Project (GEMCAS) Cardiovasc Diabetol 2007; 6: 22 401. Irwin DE, Milsom I, Hunskaar S et al. PopulationBased Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study, 04 October 2006 Eur Urol 2006;50(6):1306–15. 402. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–78. 403. Hammarsten J, Hogstedt B Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39: 151-8. 404. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia Eur Urol 2007; 51: 199-206 405. Kaplan S, Fisch H, Berriman SJ. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms, sexual dysfunction, and components of the metabolic syndrome J Urol 2007; 177(Suppl): 497-8, Abstract 1508. 406. Kristal AR, Arnold KB, Schenk JM et al Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial J Urol 2007; 177: 1395-400 407. Desgrandchamps F, Haab F, Coloby P, Slama A, Gaudin AF. Instant 2006: cardiometabolic markers in subjects with lower urinary tract symptoms in the French general population Eur Urol Suppl 2008; 7: 130, Abstract 237. 408. Lee RK, Chung D, Bilal Chughtai,. Te AE, Кaplan SA. James Buchanan Brady Foundation, Department of Urology, Weill Medical College of Cornell University, New York, NY, and Mount Sinai Hospital, Department of Surgery, Division of Urology, Chicago, IL, USA. Accepted for publication 17 August 2011. 409. Cinar A, Hall SA, Link CL et al. Cluster analysis and lower urinary tract symptoms in men: fi ndings from the Boston Area Community Health Survey.BJU Int 2008 ; 101: 1247 56. 157 410. Kim GW, Doo SW, Yang WJ, Song YS. Effects of obesity on prostate volume and lower urinary tract symptoms in Korean men. Korean J Urol 2010; 51: 344 7. 411. Ponholzer A, Temml C, Obermayr RP et al. The association between lower urinary tract symptoms and renalfunction in men: a cross-sectional and 5- year longitudinal analysis. J Urol 2006; 175:1398 402. 412. Subak LL, Wing R, West DS et al. Weight loss to treat urinary incontinence in overweight and obese women. NEngl J Med 2009 ; 360: 481 90. 413. Khoo J, Piantadosi C, Worthley S, Wittert GA. Effects of a low-energy diet on sexual function and lower urinarytract symptoms in obese men. Int J Obes 2010 ; 34: 1396 403. 414. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. EurUrol2008 ; 53: 1228 35. 415. Cigolini M, Targher G, Tonoli M, Manara F, Muggeo M, De Sandre G. Hyperuricaemia: relationships to body fat distribution and other components of the insulin resistance syndrome in 38-year-old healthy men and women. Int J Obes Relat Metab Disord. 1995;19:92–6. 416. Takahashi S, Yamamoto T, Tsutsumi Z, Moriwaki Y, Yamakita J, Higashino K. Close correlation between visceral fat accumulation and uric acid metabolism in healthy men. Metabolism. 1997;46:1162–5. 417. Takahashi S, Yamamoto T, Tsutsumi Z, Moriwaki Y, Hada T. Increased visceral fat accumulation in patients with primary gout. Adv Exp Med Biol. 2000;486:131–4. 418. Takahashi S, Moriwaki Y, Tsutsumi Z, Yamakita J, Yamamoto T, Hada T. Increased visceral fat accumulation further aggravates the risks of insulin resistance in gout. Metabolism. 2001;50:393–8. 419. Tamba S, Nishizawa H, Funahashi T, Okauchi Y, Ogawa T, Noguchi M, et al. Relationship between the serum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese Men. Int Med. 2008;47:1175–80. 420. Ichikawa N, Taniguchi A, Urano W, Nakajima A, Yamanaka H. Comorbidities in patients with gout. Nucleosides Nucleotides Nucleic Acids. 2011;30:1045–50. 421. Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci. 2005;20:1029–33. 422. Fraile JM, Torres RJ, de Miguel ME, Martinez P, Lundelin KJ, Vazquez JJ, et al. Metabolic syndrome characteristics in gout patients. Nucleosides Nucleotides Nucleic Acids. 2010;29:325–9.1 423. Inokuchi T, Tsutsumi Z, Takahashi S, Ka T, Moriwaki Y, Yamamoto T. Increased frequency of metabolic syndrome and its individual metabolic abnormalities in Japanese patients with primary gout. J Clin Rheumatol. 2010;16:109–12. 424. Yoo HG, Lee SI, Chae HJ, Park SJ, Lee YC, Yoo WH. Prevalence of insulin resistance and metabolic syndrome in patients with gouty arthritis. Rheumatol Int. 2011;31:485–91. 425. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination |